Trost Jeffrey C, Hillis L David
Department of Internal Medicine (Cardiology Division), Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Am J Cardiol. 2006 May 1;97(9):1391-8. doi: 10.1016/j.amjcard.2005.11.070. Epub 2006 Mar 20.
Intra-aortic balloon counterpulsation (IABP) is sometimes used in critically ill patients with cardiac disease. By increasing diastolic arterial pressure and decreasing systolic pressure, it reduces left ventricular afterload. IABP may be beneficial in subjects with cardiogenic shock, mechanical complications of myocardial infarction, intractable ventricular arrhythmias, or advanced heart failure or those who undergo "high-risk" surgical or percutaneous revascularization, but the evidence to support its use in these patient groups is largely observational. Contraindications to IABP include severe peripheral vascular disease as well as aortic regurgitation, dissection, or aneurysm. The potential benefits of IABP must be weighed against its possible complications (bleeding, systemic thromboembolism, limb ischemia, and, rarely, death).
主动脉内球囊反搏(IABP)有时用于患有心脏病的重症患者。通过增加舒张期动脉压和降低收缩压,它可减轻左心室后负荷。IABP可能对心源性休克、心肌梗死机械并发症、顽固性室性心律失常或晚期心力衰竭患者,或那些接受“高风险”手术或经皮血管重建术的患者有益,但支持在这些患者群体中使用IABP的证据大多为观察性证据。IABP的禁忌症包括严重外周血管疾病以及主动脉瓣关闭不全、夹层或动脉瘤。必须权衡IABP的潜在益处与其可能的并发症(出血、全身性血栓栓塞、肢体缺血,以及罕见的死亡)。